A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Inclusion Criteria

• •Must have histological or cytological evidence of a diagnosis of cancer that is not amenable to curative therapy.
• •Part B: Must have a type of malignancy that is being studied.
• •Part A and Part B (ovarian cancer cohort only): Must be willing to undergo pretreatment and on-treatment core needle or excisional tumor biopsies.
• •Part A (all cohorts): Have the presence of measureable and /or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
• •Part B (all cohorts): Have the presence of measurable disease as defined by the RECIST 1.1.
• •Have adequate normal organ and marrow function, including the following:
• •* Absolute neutrophil count ≥ 1.5 x 10⁹/Liters (L) (1500/cubic millimeters)
• •* Platelet count ≥ 100 x 10⁹/L (≥100,000/cubic millimeters)
• •* Hemoglobin ≥9 grams per deciliter or ≥5.6 millimoles per liter
• •* Serum Creatinine ≤1.5 × institutional upper limit of normal (ULN)
• •* Total bilirubin ≤1.5 × institutional ULN
• •* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN OR ≤5 × institutional ULN for participants with liver metastases
• •* International normalized ratio (INR) or prothrombin time (PT) INR ≤1.5 × institutional ULN or PT ≤5 seconds above institutional ULN
• •* PTT or activated partial thromboplastin time (aPTT) ≤5 seconds above institutional ULN
• •* Thyroid stimulating hormone (TSH) OR free thyroxine (T4) within the normal limits
• •Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.